[et_pb_section fb_built=\u00bb1″ fullwidth=\u00bbon\u00bb _builder_version=\u00bb4.16″ da_disable_devices=\u00bboff|off|off\u00bb global_colors_info=\u00bb{}\u00bb da_is_popup=\u00bboff\u00bb da_exit_intent=\u00bboff\u00bb da_has_close=\u00bbon\u00bb da_alt_close=\u00bboff\u00bb da_dark_close=\u00bboff\u00bb da_not_modal=\u00bbon\u00bb da_is_singular=\u00bboff\u00bb da_with_loader=\u00bboff\u00bb da_has_shadow=\u00bbon\u00bb][et_pb_fullwidth_slider use_text_overlay=\u00bbon\u00bb text_overlay_color=\u00bbrgba(6,66,58,0.25)\u00bb _builder_version=\u00bb4.16″ custom_padding=\u00bb83px||65px|||\u00bb auto=\u00bbon\u00bb auto_ignore_hover=\u00bbon\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_slide heading=\u00bbPublicaciones\u00bb use_bg_overlay=\u00bboff\u00bb use_text_overlay=\u00bbon\u00bb arrows_custom_color=\u00bb#2d788c\u00bb dot_nav_custom_color=\u00bb#2d788c\u00bb text_border_radius=\u00bb10px\u00bb _builder_version=\u00bb4.16″ header_font=\u00bb|700|||||||\u00bb header_text_align=\u00bbcenter\u00bb body_text_align=\u00bbcenter\u00bb background_enable_color=\u00bboff\u00bb use_background_color_gradient=\u00bbon\u00bb background_color_gradient_direction=\u00bb90deg\u00bb background_color_gradient_stops=\u00bbrgba(0,0,0,0) 0%|rgba(0,0,0,0) 100%\u00bb background_color_gradient_overlays_image=\u00bbon\u00bb background_color_gradient_start=\u00bbrgba(0,0,0,0)\u00bb background_color_gradient_end=\u00bbrgba(0,0,0,0)\u00bb background_image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/3d-objects-of-hepatitis-b-viruses-in-abstract-plasma.jpg\u00bb background_enable_image=\u00bbon\u00bb text_orientation=\u00bbcenter\u00bb header_text_shadow_style=\u00bbpreset1″ header_text_shadow_color=\u00bb#706f6f\u00bb body_text_shadow_style=\u00bbpreset1″ body_text_shadow_color=\u00bb#706f6f\u00bb text_shadow_style=\u00bbpreset1″ text_shadow_color=\u00bb#706f6f\u00bb global_colors_info=\u00bb{}\u00bb sticky_transition=\u00bbon\u00bb][\/et_pb_slide][\/et_pb_fullwidth_slider][\/et_pb_section][et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.16″ da_disable_devices=\u00bboff|off|off\u00bb global_colors_info=\u00bb{}\u00bb da_is_popup=\u00bboff\u00bb da_exit_intent=\u00bboff\u00bb da_has_close=\u00bbon\u00bb da_alt_close=\u00bboff\u00bb da_dark_close=\u00bboff\u00bb da_not_modal=\u00bbon\u00bb da_is_singular=\u00bboff\u00bb da_with_loader=\u00bboff\u00bb da_has_shadow=\u00bbon\u00bb][et_pb_row module_id=\u00bbpress\u00bb _builder_version=\u00bb4.16″ custom_padding=\u00bb||0px|||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.16″ global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.25.0″ custom_padding=\u00bb||0px|||\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n
Find here relevant scientific publications and technical articles – including from TherVacB project partners. Scroll down to read more about chronic hepatitis B, the virus, screening and testing for viral hepatitis C, B and D, therapeutic vaccination, and cure research as welll as ethical and practical considerations of patient recruitment into clinical trials<\/span>.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.16″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.16″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_blurb title=\u00bbTowards a cure for hepatitis B – EC CORDIS platform features the TherVacB project\u00bb alt=\u00bbSocial Media Recruitment as a Potential Trigger for Vulnerability: Multistakeholder Interview Study\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20230522″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb hover_enabled=\u00bb0″ header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0″]<\/p>\n 8 August 2025 | EU CORDIS News \u2013 European Commission<\/span><\/p>\n The European Commission\u2019s Community Research and Development Information Service, the CORDIS platform, features the TherVacB project for advancing a therapeutic vaccine against chronic hepatitis B (HBV). The article highlights the start of the multinational trial in summer 2025 and recognises TherVacB\u2019s contribution to developing curative, immune-based therapies for HBV. Read the article directly on the CORDIS platform in English, German, Spanish, Italian, and other languages. <\/p>\n https:\/\/cordis.europa.eu\/article\/id\/461120-towards-a-cure-for-hepatitis-b [\/et_pb_blurb][et_pb_blurb title=\u00bbPerceptions of stigma among patients with hepatitis B in Germany: Cross-sectional survey\u00bb alt=\u00bbSocial Media Recruitment as a Potential Trigger for Vulnerability: Multistakeholder Interview Study\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20230522″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n 13 June 2025 | JMIR Human Factors, Volume 9 (2025)<\/span><\/p>\n The key question discussed in this scientific publication is: How do people in Germany experience stigma related to hepatitis B? Most interdisciplinary research on hepatitis B stigma comes from outside Europe. To address this gap, TherVacB team at the Institute of History and Ethics in Medicine at TUM-MRI (Munich, Germany)<\/a> conducted a study with 195 patients across Germany, supported by TherVacB clinical centres in Munich, Hannover, and Leipzig<\/a>. The findings show that individuals who speak a language other than German, place a high value on privacy, or keep their diagnosis secret are more likely to feel stigmatized. In contrast, age, gender, and education had no influence on perceived stigma. While stigma levels were generally lower than in studies from Asia, cultural and social factors still play a key role. These results from TherVacB underline the need to raise awareness among healthcare professionals and support targeted community outreach. <\/p>\n https:\/\/formative.jmir.org\/2025\/1\/e66379\/<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=\u00bbScientific and medical evidence informing expansion of hepatitis B treatment guidelines\u00bb alt=\u00bbSocial Media Recruitment as a Potential Trigger for Vulnerability: Multistakeholder Interview Study\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20230522″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n 23 July 2025 | The Lancet Gastroenterology & Hepatology<\/span><\/p>\n This scientific article explores whether current treatment guidelines for hepatitis B are too narrow\u2014and whether more people could benefit from antiviral therapy. Today\u2019s treatments can suppress the virus and protect the liver, but they do not offer a cure. Global guidelines typically recommend treatment only for people with high viral load and signs of liver damage\u2014criteria that often require testing not widely available in low-resource settings. As a result, fewer than 3% of people living with hepatitis B currently receive treatment. This article discusses the risks and benefits of expanding treatment eligibility, highlighting the potential for earlier and broader intervention to reduce long-term liver damage and cancer risk. TherVacB researchers Markus Cornberg and Patrick Kennedy, together with Thomas Tu (ICE-HBV) and others, contributed to this important publication, which supports global hepatitis B elimination goals by promoting more inclusive treatment strategies. <\/p>\n https:\/\/www.thelancet.com\/journals\/langas\/article\/PIIS2468-1253(25)00053-6\/abstract<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=\u00bbPatient and public health perspectives to inform expansion of hepatitis B treatment guidelines\u00bb alt=\u00bbSocial Media Recruitment as a Potential Trigger for Vulnerability: Multistakeholder Interview Study\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20230522″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n 23 July 2025 | The Lancet Gastroenterology & Hepatology<\/span><\/p>\n This scientific article discusses the need to broaden access to hepatitis B treatment as part of a global public health strategy. Expanding treatment could improve lives and support progress toward hepatitis B elimination. Chronic infection affects millions worldwide and has serious physical, emotional, and social impacts. While antiviral therapy can prevent liver damage and improve quality of life, access remains limited\u2014especially in low-resource settings. The authors argue that treatment decisions should consider public health and patient-centred perspectives, not just clinical criteria. They highlight the benefits of earlier access, including reduced disease burden and better outcomes, and outline implementation challenges and data gaps. The publication was led by an international team of researchers from the Hepatitis B Foundation, ICE-HBV, the World Hepatitis Alliance, and academic centres in the US, UK, Australia, Egypt, and Europe. Together, they call for a more inclusive approach to treatment that supports global hepatitis B elimination goals. <\/p>\n https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S2468125325000524?dgcid=author<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=\u00bbEASL Clinical Practice Guidelines on the management of hepatitis B virus infect\u00bb alt=\u00bbSocial Media Recruitment as a Potential Trigger for Vulnerability: Multistakeholder Interview Study\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20230522″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n August 2025, first published online 9 May 2025 | Journal of Hepatology, Volume 83<\/span><\/p>\n Updated clinical guideline supports better care for hepatitis B worldwide: Hepatitis B remains a major global health challenge, with over 250 million people affected and many at risk of serious liver disease. The newly updated clinical practice guideline from the European Association for the Study of the Liver (EASL) provides practical, evidence-based recommendations to improve diagnosis, treatment, and long-term care. It is designed for all healthcare professionals involved in HBV care, from general practitioners to specialists, and includes specific guidance for both high- and low-resource settings. The guideline highlights the importance of early detection, personalised care, simplified treatment approaches, and new definitions of functional cure. TherVacB team researchers Markus Cornberg (Chair of the EASL Clinical Practice Guideline Panel), Patrick Kennedy, and Sabela Lens contributed \u2013 with other scientists – in developing this important tool, which supports the global goal of hepatitis B elimination. <\/p>\n https:\/\/www.journal-of-hepatology.eu\/article\/S0168-8278(25)00174-6\/fulltext?s=35<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=\u00bbSocial Media Recruitment as a Potential Trigger for Vulnerability: Multistakeholder Interview Study \u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/social-media-recruitment-as-a-potential-trigger-for-vulnerability-multistakeholder-interview-study.png\u00bb alt=\u00bbSocial Media Recruitment as a Potential Trigger for Vulnerability: Multistakeholder Interview Study\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20230522″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n 30 December 2024 | JMIR Human Factors, Volume 11<\/span><\/p>\n Clinical studies increasingly use social media to recruit participants, yet little research has examined the ethical challenges\u2014especially when targeting individuals in vulnerable situations. This study explores expert and patient perspectives on how social media recruitment can both reduce and amplify vulnerabilities. As part of the international TherVacB EU research project testing a hepatitis B vaccine, the authors conducted 30 interviews with external experts from various fields and 6 patients with hepatitis B. Insights from the study offer practical guidance for minimizing risks while maintaining the benefits of social media recruitment. The study highlights the need for researchers to anticipate ethical challenges and proactively apply strategies that promote both inclusivity and participant protection. <\/p>\n https:\/\/humanfactors.jmir.org\/2024\/1\/e52448<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=\u00bbThe urgent need to end hepatitis B stigma and discrimination\u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/The-urgent-need-to-end-hepatitis-B-stigma-and-discrimination.png\u00bb alt=\u00bbThe urgent need to end hepatitis B stigma and discrimination\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20230522″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n 17 December 2024 \/ 10 January 2025 | The Lancet Gastroenterology & Hepatology, Volume 10<\/span><\/p>\n In this article, authors call for prioritization to end hepatitis B-related discrimination, taking into account the WHO global hepatitis report 2024.<\/p>\n https:\/\/www.thelancet.com\/journals\/langas\/article\/PIIS2468-1253(24)00389-3\/abstract<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=\u00bbA cancer-causing virus hiding in millions of Americans. Why does hepatitis B, which can lead to liver cancer, often go undetected, even though tests exist? \u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/a-cancer-causing-virus-hiding-in-millions-of-americans.jpg\u00bb alt=\u00bbA Cancer-Causing Virus Hiding in Millions of Americans\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20230522″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n 18 December 2024 | The New Yorker<\/span><\/p>\n The major U.S. popular media magazine The New Yorker prioritizes hepatitis B and its health disparities in the USA. Hepatitis B Foundation President Dr. Chari Cohen is quoted in a powerful new story about hepatitis B. <\/p>\n https:\/\/www.newyorker.com\/science\/annals-of-medicine\/a-cancer-causing-virus-hiding-in-millions-of-americans<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=\u00bbAcceptance of Social Media Recruitment for Clinical Studies Among Patients With Hepatitis B: Mixed Methods Study\u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/acceptance-of-social-media-recruitment-for-clinical-studies-among-patients-with-hepatitis-b.png\u00bb alt=\u00bbAceptaci\u00f3n del reclutamiento a trav\u00e9s de las redes sociales para estudios cl\u00ednicos entre pacientes con hepatitis B\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20230522″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]26 August 2024 | Journal of Medical Internet Research<\/em><\/span><\/p>\n This study focuses on patients with hepatitis B in Germany and examines their attitudes toward using social media<\/strong> platforms like Facebook<\/strong> and Twitter<\/strong> for recruiting participants into clinical trials<\/strong>. Hepatitis B is a chronic infectious disease<\/strong>, and patients with this condition are often seen as vulnerable, facing potential stigma<\/strong> and discrimination<\/strong>. Researchers at TherVacB\u2019s TUM-MED and at TUM, University of Bern and University of Basel surveyed 195 patients from three clinical centres in Germany and found that factors like digital literacy<\/strong>, trust in nonmedical sources, privacy<\/strong> concerns, and willingness to share their diagnosis impact their acceptance of social media recruitment. The study emphasizes how understanding these factors, including health technology acceptance<\/strong>, can help researchers design recruitment strategies while balancing ethics<\/strong> and data protection<\/strong> considerations, especially in this vulnerable group. These insights could improve enrolment<\/strong> for clinical studies in the future. <\/p>\n https:\/\/www.jmir.org\/2024\/1\/e54034<\/a>[\/et_pb_blurb][et_pb_blurb title=\u00bbPractical Benefits, Challenges, and Recommendations on Social Media Recruitment: Multi-Stakeholder Interview Study\u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/practical-benefits-challenges-and-recommendations-on-social-media-recruitment-multi-stakeholder-interview-study.png\u00bb alt=\u00bbPractical Benefits, Challenges, and Recommendations on Social Media Recruitment: Multi-Stakeholder Interview Study\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20230522″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.16″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]22 May 2023 | Journal of Medical Internet Research<\/em><\/span><\/p>\n The increasing use of social media opens new opportunities for recruiting patients for research studies. Based on semi-structured interviews with both people using social media and living with hepatitis B as well as experts in a range of disciplines, authors are exploring the practical benefits of recruiting study participants with social media and are sharing an expert summary on how to conduct social media-based recruitment. Generally, a multiplatform approach with mixed-methods recruitment is the most beneficial recruitment strategy for many research studies. The different recruitment methods complement each other and may contribute to improving the reach of the study, the recruitment accrual, and the representativeness of the sample. Importantly, an assessment of the context- and project-specific appropriateness and usefulness of social media recruitment should be carried out before designing the recruitment strategy. <\/p>\n https:\/\/www.jmir.org\/2023\/1\/e44587\/ <\/a>[\/et_pb_blurb][et_pb_blurb title=\u00bbEfficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance\u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/efficient-stabilizatio-nof-therapeutic-hepatitis-b-vaccine-components.png\u00bb alt=\u00bbEfficient stabilization of therapeutic hepatitis B vaccine components\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20221012″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.16″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n February 2023 | Journal of Hepatology<\/em><\/span><\/p>\n Induction of potent, HBV-specific immune responses is crucial to control and finally cure HBV. The therapeutic hepatitis B vaccine TherVacB<\/em> combines protein priming with a Modified Vaccinia virus Ankara (MVA)-vector boost to break immune tolerance in chronic HBV infection. Particulate protein and vector vaccine components, however, require a constant cooling chain for storage and transport, posing logistic and financial challenges to vaccine applications. Authors of this article aimed to identify an optimal formulation to maintain stability and immunogenicity of the protein and vector components of the vaccine using a systematic approach. This will facilitate global vaccine application without the need for cooling chains and is important for the development of prophylactic as well as therapeutic vaccines supporting vaccination campaigns worldwide.<\/p>\n https:\/\/www.jhep-reports.eu\/article\/S2589-5559%2822%2900175-6\/fulltext<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=\u00bbSocial media advertising for clinical studies: Ethical and data protection implications of online targeting\u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/social-media-advertising-for-clinical-studies.png\u00bb alt=\u00bbSocial media advertising for clinical studies\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20221012″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.16″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n 21 February 2023 | Big Data & Society<\/em><\/span><\/p>\n Social media advertising is gaining a foothold in the recruitment of clinical study participants, promising more yield per money spent because the technology can better reach highly specialised groups. In this article, authors point out severe societal risks posed by advertising for clinical studies on social media and call for updates of research ethics guidelines and better regulation of Big Data and inferential analytics. In conclusion, social media advertising \u2013 especially with vulnerable patient populations \u2013 is deemed unsuitable as a recruitment tool for clinical studies as long as the processing of (even anonymised) social media usage data and the training of predictive models by data analytics and artificial intelligence companies is not sufficiently regulated.<\/p>\n https:\/\/journals.sagepub.com\/doi\/10.1177\/20539517231156127<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=\u00bbEvaluaci\u00f3n del efecto de la coexpresi\u00f3n de CD70 en la respuesta de las c\u00e9lulas T CD8 en la vacunaci\u00f3n con MVA-prima proteica en ratones\u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/evaluation-of-the-effect-of-cd70-co-expression-on-cd8-t-cell-response.png\u00bb alt=\u00bbEvaluation of the Effect of CD70 Co-Expression on CD8 T Cell Response \u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20221012″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.21.0″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]21 January 2023 | Vaccines \u2013 Specia<\/em>l Issue <\/em>Hepatitis Virus Vaccine Immune Therapy<\/a><\/em><\/span><\/p>\n This article investigates the potential of CD70 co-expression during viral vector boost vaccination to improve an antigen-specific T cell response. In sum, the article presents a safe system to selectively enhance the vector-vaccine-induced CD8 T cell response to the target antigen through CD70 co-expression during boost immunization. In this respect, this study may contribute to the development and improvement of therapeutic vaccines revealing novel generic design principles and thus foster advances of current strategies to fight malignancies and persistent viral infections.<\/p>\n https:\/\/www.mdpi.com\/2076-393X\/11\/2\/245<\/a>[\/et_pb_blurb][et_pb_blurb title=\u00bbActivation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models\u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/activation-of-cd4-t-cells.png\u00bb alt=\u00bbActivation of CD4 T cells \u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20221012″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.16″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n 9 de enero de 2023 | Journal of Hepatology<\/span> Lee m\u00e1s sobre el trabajo del equipo en torno a la Prof. Dra. Ulrike Protzer y la Dra. Anna Kosinska aqu\u00ed: https:\/\/idw-online.de\/en\/news807417<\/a> [\/et_pb_blurb][et_pb_blurb title=\u00bbEvaluaci\u00f3n del efecto de la coexpresi\u00f3n de CD70 en la respuesta de las c\u00e9lulas T CD8 en la vacunaci\u00f3n con MVA-prima proteica en ratones \u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/evaluation-of-the-effect-of-cd70-co-expression-on-cd8-t-cell.png\u00bb alt=\u00bbEvaluaci\u00f3n del efecto de la coexpresi\u00f3n de CD70 en c\u00e9lulas T CD8″ icon_placement=\u00bbleft\u00bb admin_label=\u00bb20221012″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.21.0″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n 21 de enero de 2023 | Vacunas – N\u00famero especial Vacuna contra el virus de la hepatitis Inmunoterapia<\/span> [\/et_pb_blurb][et_pb_blurb title=\u00bbA thermostable therapeutic vaccine is able to break immune tolerance in a mouse model of chronic hepatitis B\u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/break-immune-tolerance-in-a-mouse-model-of-chronic-hepatitis-b.jpg\u00bb alt=\u00bbbreak immune tolerance in a mouse model of chronic hepatitis B\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20221012″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.16″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n 12 de octubre de 2022 | Journal of Hepatology (JHEP) Reports<\/span> Lea m\u00e1s sobre el trabajo del equipo del laboratorio del Prof. Protzer aqu\u00ed: https:<\/a>\/\/www.dzif.de\/en\/chronic-hepatitis-b-development-thermostable-therapeutic-vaccine. https:\/\/www.jhep-reports.eu\/article\/S2589-5559(22)00175-6\/fulltext<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=\u00bbA roadmap for serum biomarkers for hepatitis B virus: current status and future outlook\u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/a-roadmap-for-serum-biomarkers-for-hepatitis-b-virus-current-status-and-future-outlook.png\u00bb alt=\u00bbA roadmap for serum biomarkers for hepatitis B virus: current status and future outlook\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20220720″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.16″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]20 July 2022 | Nature Reviews Gastroenterology & Hepatology<\/span> 30 de marzo de 2022 | Nature<\/span> [\/et_pb_blurb][et_pb_blurb title=\u00bbImmunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection\u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/immunogenicity-and-antiviral-response-of-therapeutic-hepatitis-b-vaccination-in-a-mouse-model-of-hbeag-negative.png\u00bb alt=\u00bbClosing in on a cure for hepatitis B\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20210731″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.16″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n 31 July 2021 | Vaccines<\/span> [\/et_pb_blurb][et_pb_blurb title=\u00bbHepatitis B, C and D virus prevalence in children and adults in Mbeya Region, Tanzania: results from a cohort study 2002 – 2009″ image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/hepatitis-b-c-and-d-virus-prevalence-in-children-and-adults-in-mbeya-region-tanzania.png\u00bb alt=\u00bbHepatitis B, C and D virus prevalence in children and adults in Mbeya Region, Tanzania\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20210706″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.16″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb saved_tabs=\u00bball\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n 6 July 2021 | The Pan African Medical Journal<\/span> [\/et_pb_blurb][et_pb_blurb title=\u00bbScreening auf Hepatitis B und C geh\u00f6rt jetzt zur Gesundheitsvorsorge\u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/screening-auf-hepatitis-b-und-c-gehort-jetzt-zur-gesundheitsvorsorge.png\u00bb alt=\u00bbClosing in on a cure for hepatitis B\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20210717″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.16″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n 17 June 2021 | Der Hausarzt.DIGITAL<\/span> [\/et_pb_blurb][et_pb_blurb title=\u00bbPD-L1 Silencing in Liver Using siRNAs Enhances Efficacy of Therapeutic Vaccination for Chronic Hepatitis B\u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/pd-l1-silencing-in-liver-using-sirnas-enhances-efficacy-of-therapeutic-vaccination-for-chronic-hepatitis-b.png\u00bb alt=\u00bbClosing in on a cure for hepatitis B\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20210318″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.16″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n 18 March 2021 | Biomolecules <\/span> [\/et_pb_blurb][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" relevant Publications Find here relevant scientific publications and technical articles – including from TherVacB project partners. Scroll down to read more about chronic hepatitis B, the virus, screening and testing for viral hepatitis C, B and D, therapeutic vaccination, and cure research as welll as ethical and practical considerations of patient recruitment into clinical trials.8 […]<\/p>\n","protected":false},"author":5,"featured_media":2838,"parent":2968,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-8514","page","type-page","status-publish","has-post-thumbnail","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.thervacb.eu\/es\/wp-json\/wp\/v2\/pages\/8514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.thervacb.eu\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.thervacb.eu\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/es\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/es\/wp-json\/wp\/v2\/comments?post=8514"}],"version-history":[{"count":17,"href":"https:\/\/www.thervacb.eu\/es\/wp-json\/wp\/v2\/pages\/8514\/revisions"}],"predecessor-version":[{"id":13769,"href":"https:\/\/www.thervacb.eu\/es\/wp-json\/wp\/v2\/pages\/8514\/revisions\/13769"}],"up":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/es\/wp-json\/wp\/v2\/pages\/2968"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/es\/wp-json\/wp\/v2\/media\/2838"}],"wp:attachment":[{"href":"https:\/\/www.thervacb.eu\/es\/wp-json\/wp\/v2\/media?parent=8514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n <\/a><\/p>\n
Los autores describen el esquema de vacunaci\u00f3n terap\u00e9utica heter\u00f3loga(TherVacB)<\/em> desarrollado recientemente, que comprende un cebado de prote\u00edna particulada seguido de un refuerzo de vector del virus vaccinia Ankara (MVA) modificado para el tratamiento del VHB.<\/em> Sin embargo, siguen sin estar claros los determinantes clave necesarios para superar la tolerancia inmunitaria espec\u00edfica del VHB. In this article, new combination adjuvants and unravel factors are studied that are essential for the antiviral efficacy of the TherVacB<\/em> vaccination scheme.<\/p>\n
https:\/\/www.journal-of-hepatology.eu\/article\/S0168-8278(22)03465-1\/fulltext#secsectitle0045<\/a>
<\/em><\/p>\n
En este art\u00edculo, el equipo de investigadores estudia el potencial de la coexpresi\u00f3n de CD70 durante la vacunaci\u00f3n de refuerzo con vectores virales para mejorar la respuesta de c\u00e9lulas T ant\u00edgeno-espec\u00edfica. En general, este estudio indica que la coexpresi\u00f3n orquestada de CD70 y un ant\u00edgeno vacunal puede ser un medio interesante y seguro de potenciar las respuestas de c\u00e9lulas T CD8 espec\u00edficas de ant\u00edgeno utilizando vacunas basadas en vectores, aunque en nuestro estudio no fue suficiente para romper la tolerancia inmunitaria.
https:\/\/www.mdpi.com\/2076-393X\/11\/2\/245<\/a><\/p>\n
La vacunaci\u00f3n terap\u00e9utica es una prometedora opci\u00f3n terap\u00e9utica para la hepatitis B cr\u00f3nica que puede permitir curar la hepatitis B cr\u00f3nica. Sin embargo, su aplicaci\u00f3n requiere cadenas de refrigeraci\u00f3n funcionales durante el transporte y el almacenamiento que dif\u00edcilmente pueden garantizarse en muchos pa\u00edses con gran demanda. In this study, the authors including Julia Sacherl, Anna D. Kosinska and Ulrike Protzer, developed thermostable vaccine components that are well tolerated and allow inducing immune responses and control the virus in preclinical mouse models even after long-term exposure to high surrounding temperatures. This will lower costs and ease application of a therapeutic vaccine and thus be beneficial for the many hepatitis B patients worldwide.<\/p>\n
<\/em><\/p>\n
\nGlobally, 296 million people are infected with hepatitis B virus (HBV), and approximately one million people die annually from HBV-related causes. Although there is a preventative vaccine and antiviral therapies suppressing HBV replication, there is no cure. Intensive efforts are under way to develop curative HBV therapies. Currently, only a few biomarkers are available for monitoring or predicting HBV disease progression and treatment response. As new therapies become available, new biomarkers to monitor viral and host responses are urgently needed. In October 2020, the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) held a workshop on HBV biomarkers. Various stakeholders from academia, clinical practice, and the pharmaceutical industry, with complementary expertise, presented and participated in panel discussions \u2013 including Ulrike Protzer, Mala Maini, and Florian van B\u00f6mmel. This Roadmap summarizes the strengths, weaknesses, opportunities, and challenges of HBV biomarkers.
\nhttps:\/\/www.nature.com\/articles\/s41575-022-00649-z<\/a>[\/et_pb_blurb][et_pb_blurb title=\u00bbEthical Issues in Social Media Recruitment for Clinical Studies: Ethical Analysis and Framework\u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/ethical-issues-in-social-media-recruitment-for-clinical-studies-ethical-analysis-and-framework.png\u00bb alt=\u00bbEthical Issues in Social Media Recruitment for Clinical Studies Ethical Analysis and Framework\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20220503″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.16″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]3 May and 7 September 2022 | The Journal of Medical Internet Research<\/span>
\nBettina M Zimmermann, Theresa Willem, Carl Justus Bredthauer, Alena Buyx<\/span>
\nSocial media recruitment for clinical studies holds the promise of being a cost-effective way of attracting traditionally marginalized populations and promoting patient engagement with researchers and a particular study. However, using social media for recruiting clinical study participants also poses a range of ethical issues. The study summarized in this paper aims to provide a comprehensive overview of the ethical benefits and risks to be considered for social media recruitment in clinical studies and develop practical recommendations on how to implement these considerations.
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9115665\/<\/a>[\/et_pb_blurb][et_pb_blurb title=\u00bbClosing in on a cure for hepatitis B\u00bb image=\u00bbhttps:\/\/www.thervacb.eu\/wp-content\/uploads\/closing-in-on-a-cure-for-hepatitis-b-1.png\u00bb alt=\u00bbClosing in on a cure for hepatitis B\u00bb icon_placement=\u00bbleft\u00bb admin_label=\u00bb20220330″ module_class=\u00bbblurbpublications\u00bb _builder_version=\u00bb4.16″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||50px||false|false\u00bb link_option_url_new_window=\u00bbon\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb18.01px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n
Elie Dolgin<\/span>
Unos ciclos finitos de tratamiento podr\u00edan controlar el virus, con la combinaci\u00f3n adecuada de f\u00e1rmacos.
Sigue leyendo para saber m\u00e1s sobre c\u00f3mo Ulrike Protzer y Mala Maini, de TherVacB, junto con otros destacados cient\u00edficos especializados en el VHB, vir\u00f3logos, inmun\u00f3logos v\u00edricos y hepat\u00f3logos de todo el mundo, han impulsado el desarrollo de un plan de acci\u00f3n centrado en la curaci\u00f3n del VHB que incluye las perspectivas de los pacientes.
https:\/\/www.nature.com\/articles\/d41586-022-00812-1<\/a><\/p>\n
Anna D Kosinska, Julia Festag, Martin M\u00fcck-H\u00e4usl, Marvin M Festag, Theresa Asen, Ulrike Protzer<\/span>
Durante el curso natural de la infecci\u00f3n cr\u00f3nica por el virus de la hepatitis B (VHB), suele perderse el ant\u00edgeno e de la hepatitis B (HBeAg), mientras que la transmisi\u00f3n directa del VHB HBeAg negativo puede dar lugar a una hepatitis B fulminante. Aunque la inducci\u00f3n de respuestas inmunitarias espec\u00edficas del VHB mediante la vacunaci\u00f3n terap\u00e9utica es una opci\u00f3n de tratamiento novedosa y prometedora para la hepatitis B cr\u00f3nica, sigue sin estar claro si la p\u00e9rdida del HBeAg puede influir en su eficacia o tolerabilidad. We therefore generated an adeno-associated virus (AAV)-vector that carries a 1.3-fold overlength HBV genome with a typical stop-codon mutation in the pre-core region and initiates the replication of HBeAg(-) HBV in mouse livers. Infection of C57BL\/6 mice established persistent HBeAg(-) HBV-replication without any detectable anti-HBV immunity or liver damage. HBV-carrier mice were immunized with TherVacB, a therapeutic hepatitis B vaccine that uses a particulate HBV S and a core protein for prime vaccination, and a modified vaccinia Ankara (MVA) for boost vaccination. The TherVacB immunization of HBeAg(+) and HBeAg(-) HBV carrier mice resulted in the effective induction of HBV-specific antibodies and the loss of HBsAg but only mild liver damage. Intrahepatic, HBV-specific CD8 T cells induced in HBeAg(-) mice expressed more IFN\u03b3 but showed similar cytolytic activity. This indicates that the loss of HBeAg improves the performance of therapeutic vaccination by enhancing non-cytolytic effector functions.
https:\/\/pubmed.ncbi.nlm.nih.gov\/34451966\/<\/a><\/p>\n
Guenter Froeschl, Michael Hoelscher, Lucas Henze Maganga, Inge Kroidl, Petra Clowes, Steffen Geis, Elmar Saathoff, Dieter Hoffmann, Ulrike Protzer, Arne Kroidl<\/span>
El \u00c1frica subsahariana tiene una alta prevalencia de infecci\u00f3n por el virus de la hepatitis B (VHB). This analysis aims at elucidating the exposure to HBV across different age groups in Mbeya Region in Tanzania and determines prevalence of hepatitis C (HCV) and hepatitis delta antigen (HDV) infections.
https:\/\/www.panafrican-med-journal.com\/content\/article\/39\/174\/full\/<\/a><\/p>\n
Ulrike Protzer<\/span>
Durante mucho tiempo se realizaron pruebas de hepatitis B y C en la revisi\u00f3n m\u00e9dica. Versicherte ab 35 Jahren k\u00f6nnen sich einmalig auf diese beiden Erkrankungen untersuchen lassen. Dr. med. Ulrich Scharmer sprach dar\u00fcber mit der Virologin Prof. Dr. med. Ulrike Protzer, M\u00fcnchen.
https:\/\/www.hausarzt.digital\/medizin\/praevention\/screening-auf-hepatitis-b-und-c-gehoert-jetzt-zur-gesundheitsvorsorge-95051.html<\/a><\/p>\n
Till Bunse, Anna D. Kosinska, Thomas Michler y Ulrike Protzer <\/span>
En la infecci\u00f3n cr\u00f3nica por el virus de la hepatitis B (VHB), las c\u00e9lulas T espec\u00edficas del virus son escasas y parcialmente disfuncionales. Therapeutic vaccination is a promising strategy to induce and activate new virus-specific T cells. In long-term or high-level HBV carriers, however, therapeutic vaccination by itself may not suffice to cure HBV. One reason is the impairment of antiviral T cells by immune checkpoints. In this study, we used small-interfering RNA (siRNA) in combination with a heterologous prime-boost therapeutic vaccination scheme (TherVacB) to interfere with a major immune checkpoint, the interaction of programmed death protein-1 (PD-1) and its ligand (PDL-1). In mice persistently replicating HBV after infection with an adeno-associated virus harboring the HBV genome, siRNA targeting PD-L1 resulted in a higher functionality of HBV-specific CD8+ T cells after therapeutic vaccination, and allowed for a more sustained antiviral effect and control of HBV in peripheral blood and in the liver. The antiviral effect was more pronounced if PD-L1 was down-regulated during prime than during boost vaccination. Thus, targeting PD-L1 using siRNA is a promising approach to enhance the efficacy of therapeutic vaccination and finally cure HBV.
https:\/\/www.mdpi.com\/2218-273X\/12\/3\/470<\/a><\/p>\n